Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Reverse Transcriptase Inhibitor
NNRT-IN-10 is a potent, selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, demonstrating EC50 values ranging from 1.16 to 18.3 nM against HIV and its mutant strains. This compound exhibits favorable pharmacokinetic properties and safety profiles, making it suitable for research applications in studying HIV-1 and AIDS. NNRT-IN-10 represents a crucial tool for advancing antiviral research targeting HIV-1 replication. -
HIV-1 Reverse Transcriptase Inhibitor
TSAO-T is a potent inhibitor of HIV-1 reverse transcriptase, a key enzyme in the retroviral replication cycle. By disrupting this enzyme's activity, TSAO-T effectively impedes viral replication, making it a valuable tool in HIV research. Its use can facilitate the study of HIV infection mechanisms and the development of novel therapeutic strategies. -
Non-Nucleoside Reverse Transcriptase Inhibitor
DPC 961 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that specifically targets HIV-1 reverse transcriptase. It exerts its biological activity by non-competitively inhibiting the enzymatic function of reverse transcriptase, effectively blocking viral replication. This compound is primarily utilized in research focused on AIDS and the mechanisms of HIV pathogenesis. -
Non-nucleoside Reverse Transcriptase Inhibitor
DPC 963 is an oral active non-nucleoside reverse transcriptase inhibitor that demonstrates an IC50 of 18 nM. This compound is primarily utilized in the study of HIV, providing insights into reverse transcription processes and potential therapeutic strategies. Its potent inhibitory activity makes DPC 963 a valuable tool for research in antiviral drug development and HIV pathogenesis. -
HIV-1 nucleotide reverse transcriptase Inhibitor
GS-9148 is a ribose-modified inhibitor of HIV-1 nucleotide reverse transcriptase, exhibiting an EC50 value of 10.6 µM. This compound demonstrates significant antiretroviral activity against HIV-1 strains with mutations at K65R, L74V, and M184V. GS-9148 is a valuable tool for research focused on HIV resistance mechanisms and the development of novel therapeutic strategies. -
Anti-HIV Nucleoside Reverse Transcriptase Inhibitor
CL-197 is a purine-based nucleoside reverse transcriptase inhibitor (NRTI) that exhibits anti-HIV activity through its selective inhibition of viral reverse transcriptase. This compound has potential applications in studying viral, oncological, and cerebrovascular diseases. Additionally, CL-197 serves as a click chemistry reagent, featuring an alkyne group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating advanced chemical research. -
HIV-1 Reverse Transcriptase Inhibitor
Opaviraline is a potent HIV-1 reverse transcriptase inhibitor. It effectively disrupts the viral replication process by targeting the reverse transcriptase enzyme, which is crucial for converting viral RNA into DNA. This compound is utilized in research focused on developing antiviral therapies and understanding HIV-1 resistance mechanisms. -
Nucleoside Reverse Transcriptase Inhibitor
Azvudine is a potent nucleoside reverse transcriptase inhibitor (NRTI) with notable antiviral activity against HIV, HBV, and HCV. It exhibits strong inhibition of HIV-1 and HIV-2, with EC50 values ranging from 0.018 to 6.92 nM, and effectively targets NRTI-resistant strains. Additionally, Azvudine serves as a click chemistry reagent, featuring an azide group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-containing molecules or those with DBCO or BCN groups, making it suitable for advanced chemical biology applications. -
Reverse Transcriptase Inhibitor
FNC-TP is the intracellular active form of the nucleoside reverse transcriptase inhibitor (NRTI) FNC, targeting reverse transcriptase enzymes. This compound exhibits potent antiviral activity against HIV, HBV, and HCV. Additionally, FNC-TP serves as a versatile click chemistry reagent, featuring an azide group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne, DBCO, or BCN-containing molecules, facilitating advanced research applications in chemical biology. -
Reverse Transcriptase Inhibitor
Lamivudine triphosphate TEA is a potent reverse transcriptase inhibitor that functions by terminating the elongation of viral nucleic acids. It effectively inhibits the reverse transcriptase of HIV and HBV, thereby obstructing viral replication. Additionally, Lamivudine triphosphate TEA targets the RNA-dependent RNA polymerase (RdRp) of the NS5B subunit in HCV, and can be incorporated into the RNA by the RdRp of SARS-CoV-2, interrupting the synthesis and leading to a decrease in mutations in the viral genome. This makes it a critical reagent for research in antiviral therapies and viral replication studies. -
Reverse Transcriptase Inhibitor
Lamivudine salicylate is a nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against HIV reverse transcriptase 1/2 and hepatitis B virus reverse transcriptase. Its oral bioavailability and ability to penetrate the central nervous system make it a valuable compound for anti-viral research. Lamivudine salicylate is widely utilized in studies focused on the treatment and management of HIV and hepatitis B infections. -
Reverse Transcriptase Inhibitor
Lamivudine triphosphate is a potent reverse transcriptase inhibitor that serves as a phosphorylated form of the nucleoside analogue Lamivudine. It effectively disrupts the replication of HIV and HBV viruses through chain termination. Additionally, Lamivudine triphosphate inhibits the RNA-dependent RNA polymerase (RdRp) activity of the NS5B subunit in hepatitis C virus, and can be incorporated into nascent RNA by the SARS-CoV-2 RdRp, thereby preventing mutations in the SARS-CoV-2 RNA. This makes it a valuable reagent for research on viral replication mechanisms and antiviral drug development. -
Nucleoside Reverse Transcriptase Inhibitor
Metacavir is a potent nucleoside reverse transcriptase inhibitor primarily targeting the hepatitis B virus (HBV). This orally active compound exhibits significant antiviral activity, making it a valuable tool in the research of antiviral therapies and the development of treatments for HBV infections. Its specificity and efficacy in inhibiting reverse transcriptase contribute to its potential application in studying hepatitis B and related disorders. -
Reverse Transcriptase Inhibitor
5'-Azido-5'-deoxythymidine is a nucleoside analogue that functions as an inhibitor of reverse transcriptase. By mimicking natural nucleosides, it integrates into viral DNA during replication, thereby terminating chain elongation and effectively inhibiting viral propagation. This compound is valuable for research into retroviral infections, including AIDS, contributing to the understanding and treatment of these diseases. -
reverse transcriptase inhibitor
Depulfavirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates exceptional antiviral activity with an IC50 of 1.1 nM against wild-type HIV-1 and maintains effectiveness (IC50 < 100 nM) against 92% of various NNRTI-resistant clinical isolates. This compound is valuable for research into HIV resistance mechanisms and the development of novel antiviral therapies. -
AMV Reverse Transcriptase Inhibitor
Limocrocin is an inhibitor of avian myeloid leukemia virus (AMV) reverse transcriptase. This compound, derived from Streptomyces limosus, exhibits significant inhibitory activity independent of variations in template-primer concentration, substrate, or carrier protein levels. However, its efficacy diminishes with increasing concentrations of AMV reverse transcriptase. Limocrocin serves as a valuable tool for research in antiviral treatment development. -
Non-nucleoside Reverse Transcriptase Inhibitor
(R)-Efavirenz is a non-nucleoside reverse transcriptase inhibitor that acts through non-competitive inhibition of the viral enzyme. It is selectively metabolized by CYP2B6 to form 8-hydroxyefavirenz, which highlights its potential as a probe for studying the CYP2B6 active site and its catalytic mechanisms. This compound serves as a valuable tool in the research of antiviral therapeutics and the pharmacokinetics of HIV treatment. -
Reverse Transcriptase Inhibitor
Trovirdine hydrochloride is an HIV reverse transcriptase inhibitor, acting as a non-nucleoside inhibitor (NNI) of the enzyme. It demonstrates significant biological activity against HIV replication, effectively achieving inhibition at nanomolar concentrations without cytotoxic effects in infected peripheral blood mononuclear cells. This compound serves as a valuable tool for research applications focused on understanding HIV therapeutics and developing more potent derivatives for enhancing antiviral strategies. -
Reverse Transcriptase Inhibitor
Mniopetal E is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by interfering with the reverse transcription process, making it valuable for research in viral replication studies and the development of antiviral therapies. Its selective inhibition of reverse transcriptase may also provide insights into nucleic acid synthesis mechanisms in various biological systems. -
Reverse Transcriptase Inhibitor
Mniopetal B is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by interfering with the reverse transcription process, which is critical for the replication of retroviruses. Its mechanism makes Mniopetal B suitable for research applications focused on virology, HIV studies, and the development of antiviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal D is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by blocking the reverse transcription process, which is essential in the life cycle of retroviruses. Mniopetal D is utilized in research applications focused on antiviral drug development and understanding retroviral replication mechanisms. -
Reverse Transcriptase Inhibitor
Mniopetal F is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. It effectively disrupts the replication cycle of retroviruses by hindering the reverse transcription process, making it a valuable tool in antiviral research. Mniopetal F can be utilized in studies focused on understanding viral mechanisms and developing therapeutic strategies against retroviral infections. -
Reverse Transcriptase Inhibitor
NNRT-IN-5 is a non-nucleoside reverse transcriptase inhibitor that exhibits potent antiviral activity against HIV. This compound functions by binding to the reverse transcriptase enzyme, disrupting the viral replication process. NNRT-IN-5 is primarily utilized in research to explore HIV mechanisms and develop novel therapeutic strategies targeting reverse transcriptase. -
Reverse Transcriptase Inhibitor
Mniopetal C is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by disrupting the reverse transcription process, making it valuable for research in molecular biology and virology. Mniopetal C can be utilized in studies focused on retroviral infections and the development of antiretroviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal A is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound has demonstrated significant ability to impede the reverse transcription process, making it a valuable tool in research focused on retroviral infections and related mechanisms. Its application extends to studies investigating viral replication, cellular responses to viral entry, and therapeutic developments targeting reverse transcription pathways. -
Nucleotide Reverse Transcriptase Inhibitor
Tenofovir disoproxil aspartate is a nucleotide reverse transcriptase inhibitor primarily targeting HIV and chronic Hepatitis B. It demonstrates potent antiviral activity by interfering with viral RNA replication, ultimately leading to reduced viral load in infected patients. This compound is essential in research aimed at developing effective therapeutic strategies against retroviral infections. -
NNRT inhibitor
MK-1439 is a non-nucleoside reverse transcriptase inhibitor -
HIV reverse transcriptase inhibitor
Dapivirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) -
NNRT inhibitor
Lersivirine (UK-453,061) is a next-generation nonnucleoside reverse transcriptase inhibitor, active against wild-type HIV-1 and several nonnucleoside reverse transcriptase inhibitor-resistant strains. -
NNRT inhibitor
Delavirdine is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). -
Transcriptase inhibitor
Abacavir sulfate is a nucleoside analog reverse transcriptase inhibitor (NRTI); guanosine analog used to treat HIV and AIDS. -
NNRT inhibitor
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. -
NNRT inhibitor
Rilpivirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. -
NRT inhibitor
Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI). -
nucleotide reverse transcriptase inhibitor
Tenofovir Disoproxil (Bis(POC)-PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
nucleotide reverse transcriptase inhibitor
Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
HIV-1 nucleotide reverse transcriptase inhibitor
Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a HIV-1 nucleotide reverse transcriptase inhibitor. -
nucleotide reverse transcriptase inhibitor
Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B. -
NNRT inhibitor
Elsulfavirine is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Viriom for the treatment and prevention of human immunodeficiency virus (HIV) infections. It is the prodrug of the active compound VM-1500A, a small molecule selective NNRTI, which prevents HIV replication. -
non-nucleoside reverse transcriptase inhibitor
Delavirdine(U 90152) is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI). -
nucleoside reverse transcriptase inhibitor
Emtricitabine S-oxide (Emtricitabine sulfoxide) is a major degradation product of Emtricitabine. Emtricitabine is a potent nucleoside reverse transcriptase inhibitor used for the treatment of HIV infection. -
HIV-1 reverse transcriptase inhibitor
beta-L-D4A is a nucleoside HIV-1 reverse transcriptase inhibitor. -
nucleoside reverse transcriptase (RT) inhibitor
4'-Ethynyl-2'-deoxyadenosine (4'-E-dA), a nucleoside reverse transcriptase (RT) inhibitor, is an antiretroviral agent which is potent against drug-resistant HIV variants, with an EC50 of 98 nM in MT-4 cells for anti-HIV-1 activity. -
XMRV inhibitor
3'-Azido-3'-deoxy-5-methylcytidine (CS-92) is a potent xenotropic murine leukemia-related retrovirus (XMRV) inhibitor with a CC50 of 43.5 μM in MCF-7 cells. -
NRTI Inhibitor
Zidovudine is a nucleoside analog reverse-transcriptase inhibitor (NRTI), a type of antiretroviral drug used for the treatment of HIV/AIDS infection. Azidothymidine decreases CRISPR-mediated homology directed repair (HDR) efficiency.
